Drug Database
PN

pneumococcal vaccine (Prevenar20 / PCV20 / PF 06482077)

✓ Approved

Pfizer, Inc. · 疫苗 · 疫苗

什么是 pneumococcal vaccine?

pneumococcal vaccine 是一种疫苗,由Pfizer, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名Prevenar20, PCV20, PF 06482077
公司Pfizer, Inc.
药物类别疫苗
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved

治疗适应症

pneumococcal vaccine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsPneumococcal infection✓ Approved

相关研究文献

PubMedBMJ public health2026-11-18

Decomposition of disparities in influenza and pneumococcal vaccination coverage by immigrant status among older adults in Canada: results from the Canadian longitudinal study on aging (CLSA).

Kim Ji Yoon JY, Yang Seungmi S, Russell W Alton WA, Sulis Giorgia G et al.

Immigrant older adults in Canada have lower coverage for influenza and pneumococcal vaccinations compared with non-immigrants, yet the specific factors contributing to these disparities remain underexplored. Using data from the Canadian Longitudinal Study on Aging, we applied a non-linear Blinder-Oaxaca decomposition method to assess the contributions of demographic, socioeconomic, health-related and neighbourhood characteristics to influenza (n=23 214) and pneumococcal (n=22 235) vaccination disparities. Overall, the disparities were driven by differences in associations between characteristics and vaccination outcomes (ie, coefficient estimates), rather than by differences in distributions of characteristics (ie, covariate estimates). Some characteristics contributed to widening and others to narrowing disparities but the contributions varied by vaccine type. The combined contributions of all covariates were negative (influenza: -1.95 (95% CI -2.80 to -1.11); pneumococcal: -0.24 (95% CI -1.15 to 0.67)) suggesting that if immigrants had the same distributions of characteristics and associations between characteristics and vaccination as non-immigrants, vaccination disparities would widen. Unmeasured and/or unknown variables (ie, the intercept) (influenza: 1.67 (95% CI -24.05 to 27.38); pneumococcal: 22.60 (95% CI -3.42 to 48.61)) had a substantial role in explaining disparities in both outcomes. These results suggest that immigrants have lower vaccination coverage despite being more likely to have traits associated with a higher likelihood of vaccination, some of which were more strongly associated with vaccination for immigrants. Commonly researched determinants of vaccination do not explain the lower vaccination coverage among older Canadian immigrants. Future research should investigate additional determinants, particularly societal and structural factors, that may shape vaccination decisions differently for immigrants, focusing on individual vaccine types. Such insights will inform the development of targeted interventions to address vaccine inequities in Canada.

PMID 43047962
阅读全文 →
PubMedPediatric blood & cancer2026-11-18

Total Serum IgG Is a Poor Surrogate for Pneumococcal Protection Following Hematopoietic Stem Cell Transplantation in Pediatric Sickle Cell Disease.

Needum Alonzo A, Tinsley Hailey H, Oh Kendall K, Doherty Erin E et al.

Children with sickle cell disease (SCD) have functional asplenia and a higher risk of invasive pneumococcal disease. While allogeneic hematopoietic stem cell transplantation (HSCT) is curative, post-transplant immune reconstitution is heterogeneous. Total serum immunoglobulin G (IgG) is widely used to gauge humoral recovery yet may not reflect pneumococcal serotype-specific seroprotection. We performed a single-center retrospective cohort study of pediatric patients with SCD who underwent myeloablative matched sibling donor HSCT at Texas Children's Hospital between 2005 and 2024 and obtained pneumococcal serotype-specific antibody titers at approximately 1 year. Seroprotection was defined as an antibody concentration ≥1.3 µg/mL in ≥70% of 14 tested serotypes. Longitudinal total IgG, IgA, IgM, tetanus titers, and lymphocyte subsets (CD3+, CD4+, CD8+, CD19+) were analyzed. Receiver operating characteristic (ROC) analysis and penalized multivariable logistic regression were performed (n = 51). Of 51 patients, 32 (62.7%) achieved pneumococcal serotype-specific protection at approximately 1 year. Total IgG correlated weakly with protection at all time points (r = 0.28-0.38). Day +365 total IgG did not differ between protected and unprotected patients (p = 0.134); at commonly used thresholds between 400 and 600 mg/dL, sensitivity was 97%, but specificity was 0%, and all unprotected patients exceeded 600 mg/dL. Day +365 IgG showed limited discrimination (AUC 0.63). Broad quantitative lymphocyte subsets were also not significantly correlated with the proportion of protective pneumococcal serotypes. No invasive pneumococcal disease occurred during follow-up. Normal total serum IgG does not reliably identify pneumococcal serotype-specific seroprotection after HSCT in pediatric SCD. Serotype-specific antibody assessment provides information not captured by total IgG alone.

PMID 43049263
阅读全文 →
PubMedMediterranean journal of hematology and infectious diseases2026-11-18

Antimicrobial Management Following Positive Pneumococcal Urinary Antigen Testing in Hospitalized Community-Acquired Pneumonia: A Retrospective Cohort Study.

Donga Maria M, Gorgulho Ana A, Bartilotti Francisca F, Mbanze Dara D et al.

Pneumococcal urinary antigen testing (PUAT) rapidly supports pneumococcal etiology in community-acquired pneumonia (CAP), but how positive results are incorporated into antimicrobial management in routine care remains uncertain. To characterize antimicrobial stewardship actions implemented after a positive PUAT result became available in hospitalized adults with CAP, identify potential areas for improving guideline-concordant antimicrobial management, and compare clinical outcomes according to individual stewardship measures. We conducted a retrospective observational cohort study at a Portuguese tertiary hospital including adults hospitalized with CAP and positive PUAT between January 2020 and December 2024. The primary endpoint was antimicrobial spectrum narrowing. Post-PUAT atypical coverage optimization and intravenous-to-oral switch were analyzed separately. Among 332 episodes, antimicrobial spectrum narrowing occurred in 30 (9.0%), after a median of 3 days (Q1-Q3, 2-4). De-escalation to ampicillin or amoxicillin occurred in 7 episodes (2.1%). Post-PUAT atypical coverage optimization occurred in 158 episodes (47.6%) and intravenous-to-oral switch in 71 (21.4%). Narrowing and intravenous-to-oral switch were associated with shorter length of stay in unadjusted analyses, although these associations were exploratory and potentially influenced by clinical stability. In hospitalized PUAT-positive CAP, antimicrobial spectrum narrowing was uncommon, whereas atypical coverage optimization was the most frequent prescribing change. Structured post-result reassessment pathways may help improve guideline-concordant antimicrobial management.

PMID 43048189
阅读全文 →
PubMedGastroenterology report2026-11-18

Evaluating the evidence of health consequences of celiac disease: an umbrella review of meta-analyses.

Tsali Lampriani L, Chalitsios Christos V CV, Pagkalidou Eirini E, Ntzani Evangelia E et al.

Celiac disease (CeD) extends beyond the gastrointestinal tract and may affect multiple organ systems. However, the credibility of reported extra-intestinal associations remains uncertain. We searched PubMed and Scopus until August 2024 for systematic reviews and meta-analyses of observational studies evaluating associations between CeD and any health-related outcome. Each meta-analytic association was appraised using established credibility criteria. Thirteen publications met eligibility, reporting 26 meta-analytic associations, 17 of which were nominally statistically significant (P < 0.05). One association achieved strong evidence: CeD and higher risk of thyroid disease evaluated across all ages (odds ratio [OR] = 3.09, 95% CI: 2.33-4.09, nstudies = 12, I2 = 40%). Three associations reached highly suggestive evidence: CeD and higher risk of pneumococcal infection at all ages (OR = 1.66, 95% CI: 1.43-1.92, nstudies = 3, I2 = 0%) and among children/adolescents, lower bone mineral content (standardized mean difference [SMD] = -0.65, 95% Cl: -0.83 to -0.48, nstudies = 15, I2 = 67%), and lower areal bone mineral density (SMD = -0.80, 95% Cl: -1.03 to -0.56, nstudies=15, I2 = 72%). Most meta-analyses were based on case-control or cross-sectional studies, while all studies contributing to pneumococcal infection had a cohort design. Suggestive evidence supported five associations, namely CeD and higher risk of any fracture and psoriasis (all ages), insomnia (children, adults), and lower height and body weight (children/adolescents). Eight associations showed weak evidence, and the remaining were not statistically significant. Four meta-analytic associations between CeD and higher risk of thyroid disease, pneumococcal infection, and lower bone mass and density reached high credibility, highlighting the potential systemic nature of CeD. Prospective studies are needed to strengthen this evidence. This synthesis may inform the future research agenda in this understudied field and prevention strategies aimed at mitigating CeD-related morbidity.

PMID 43048577
阅读全文 →
PubMedFrontiers in public health2026-11-18

Characteristics of adverse events of inactivated quadrivalent influenza vaccine in healthy populations: a meta-analysis based on randomized controlled trials.

Kang Liuyang L, Yang Jing J, Cheng Jingru J, Tang Shaowen S et al.

Influenza constitutes a critical global public health issue, and quadrivalent inactivated influenza vaccine (QIV) is widely used, yet systematic analyses of its adverse events (AEs) remain lacking. This meta-analysis aimed to characterize AEs following QIV vaccination in healthy populations. We searched for randomized controlled trials (RCTs) of QIV vaccination in healthy populations, extracted AE data from QIV groups, pooled incidence rates, and compared the risks of AEs between QIV and trivalent influenza vaccine (TIV) using a random-effects model. Subgroup analyses, meta-regression, and sensitivity analyses were applied to explore heterogeneity and result robustness. Publication bias was evaluated utilizing Begg's and Egger's tests. A total of 29 studies published from 2008 to 2025 were included, involving 28,410 participants with 8,197 reported AEs in total. The overall incidence of AEs after QIV vaccination in healthy populations was 43% (95% CI: 31%-54%), with an incidence of 27% (95% CI: 18%-37%) for local AEs and 20% (95% CI: 14%-26%) for systemic AEs. The incidence of SAEs was 0.96%. The QIV group showed significantly elevated risks of overall and local AEs relative to TIV (P < 0.05), while no significant differences were detected in systemic AEs and SAEs between the two groups (P > 0.05). Heterogeneity was associated with study period, study region, AE collection duration, and vaccine origin. Sensitivity analyses and publication bias analyses confirmed result stability. This study summarizes AE incidence and features after QIV in healthy populations, supporting clinical vaccination and post-vaccination safety surveillance with exploratory data. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251233388, identifier CRD420251233388.

PMID 43047547
阅读全文 →
PubMedJournal of nanobiotechnology2026-11-18

Baculovirus-based production of virus-like particles for avian influenza: development, immunogenicity, and cross-protection against H5 and H7 AIVs.

He Yanjuan Y, Dong Yajing Y, Kong Dexin D, Chen Huixin H et al.

The persistent threat of H5 and H7 highly pathogenic avian influenza (HPAI) necessitates effective broad-spectrum vaccines. This study systematically evaluated the immunogenicity and protective efficacy of H5N6 virus-like particle (H5N6-VLP) vaccine and subsequently developed a trivalent VLP vaccine (H5N6-H5N8-H7N9-VLP) using the baculovirus expression system (BEVS). Production of H5N6-VLP was optimized at a multiplicity of infection (MOI) of 0.1 to achieve efficient assembly. The H5N6-VLP vaccine induced potent immune responses in specific-pathogen-free (SPF) chickens, providing 100% protection against homologous H5N6-GD154 virus when the HA titer reached 9 log2. Compared with traditional inactivated vaccines, the H5N6-VLP vaccine induced faster humoral immune responses and higher CD8⁺ T cell proportions. The HI seroconversion rate was 30% on day 7 post-immunization (0% for inactivated vaccine), reached 100% by day 10, while it was only 80% on day 14 for the inactivated vaccine. Furthermore, the protective efficacy of the H5N6-VLP vaccine was associated with increased IFN‑γ expression and elevated proportions of B cells and CD8⁺ T cells. Although both vaccines provided complete homologous protection, the H5N6-VLP vaccine showed better cross-protection against the heterologous H5N1-D889 strain (70% vs. 40%). A delayed challenge experiment further demonstrated that the H5N6-VLP vaccine induced durable immunity, with HI titers remaining above the protective threshold and 100% protection against homologous challenge at 8 weeks post-immunization. Based on these findings, a trivalent H5N6-H5N8-H7N9-VLP vaccine was developed. The trivalent vaccine induced substantial antibody responses and provided complete protection against parental and circulating strains, with efficacy comparable to a commercial inactivated vaccine and no detectable antigenic interference between components. Our findings highlight the potential of the BEVS-derived H5N6-VLP vaccine, particularly its early antibody induction, which allows rapid flock protection during acute HPAI outbreaks, and its cross-reactivity against heterologous strains. Furthermore, the trivalent vaccine formulation extends the potential application of this VLP platform for broad-spectrum HPAI control.

PMID 43046102
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多pneumococcal vaccine